BioMimetic Amends Augment Bone Graft PMA, Expects Approval By 2014

BioMimetic Therapeutics submits PMA amendment for its Augment bone graft device to address questions raised by FDA in a “not approvable” letter disclosed in January.

More from Regulation

More from Policy & Regulation